Gossamer Bio reports clinical, financial, and corporate updates tied to seralutinib, its investigational inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Recurring developments include Phase 3 study results, regulatory pathway updates, collaboration activity with Chiesi Group, quarterly financial results, and capital allocation updates.
Company news also covers Nasdaq Rule 5635(c)(4) employment inducement grants under the 2023 Employment Inducement Incentive Award Plan, investor conference participation, and business development or resource-allocation actions related to its pulmonary hypertension strategy.
Gossamer Bio (GOSS) submitted its first U.S. new drug application for seralutinib to treat pulmonary arterial hypertension.
The application draws on the Phase 3 PROSERA study as one adequate and well-controlled investigation, with confirmatory evidence from the Phase 2 TORREY study and supportive analyses. At a June 2026 pre-NDA meeting, the FDA characterized PROSERA’s statistical significance and the magnitude of its treatment effect as review issues rather than filing issues. The FDA has yet to decide whether to accept the application for filing; Gossamer says that decision could come later in 2026. The agency will assess the efficacy and safety evidence during its review of the complete application.
Gossamer Bio (GOSS) appointed investor Greg Ciongoli to its Board of Directors, effective September 16, 2026, and named him to the Audit Committee.
Ciongoli is Founder and Managing Partner of Boston-based Adiumentum Capital Management, launched in April 2024, and previously was a Partner at the Baupost Group, working on public and private equity investments. He also serves on the boards of REGENXBIO, Zymeworks and Atara Biotherapeutics. The company said his investment background and focus on value creation will support Gossamer Bio as it advances seralutinib for pulmonary hypertension toward potential FDA approval.
Gossamer Bio (GOSS) implemented a 1-for-80 reverse stock split of its common stock and a proportional reduction of authorized shares, effective 11:59 p.m. Eastern Time on September 10, 2026. Trading on a split-adjusted basis on the Nasdaq Global Select Market is expected to begin at the September 11, 2026 market open under the existing ticker and a new CUSIP of 38341P 201.
Every 80 pre-split shares were automatically combined into 1 share, with no fractional shares issued; holdings are rounded up to the nearest whole share. Authorized common shares were reduced from 4,000,000,000 to 50,000,000, and total authorized capital stock from 4,070,000,000 to 120,000,000. Conversion and exercise terms for convertible notes, warrants and equity awards were proportionately adjusted, and reserved shares under equity plans reduced. The reverse split is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement by the October 5, 2026 deadline.
Gossamer Bio (GOSS) will implement a 1-for-80 reverse stock split of its common stock, effective 11:59 p.m. ET on September 10, 2026.
Trading on a split-adjusted basis on the Nasdaq Global Select Market is expected to begin on September 11, 2026 under the symbol GOSS and new CUSIP 38341P 201. The reverse split, approved by stockholders on July 14, 2026, is intended to help regain compliance with Nasdaq’s minimum bid price requirement. Every 80 shares will be reclassified into 1 share, with fractional entitlements rounded up to the nearest whole share. Authorized common shares will be reduced from 4,000,000,000 to 50,000,000, and total authorized capital stock from 4,070,000,000 to 120,000,000, with outstanding convertible and equity instruments adjusted proportionately.
Gossamer Bio (GOSS)/b) will present at the Cantor Global Healthcare Conference, where it will discuss its clinical-stage work on seralutinib for pulmonary hypertension.The presentation is scheduled for September 9, 2026 at 10:55 AM ET in New York City, with a webcast available for remote participants and opportunities for 1x1 meetings.
Gossamer Bio (Nasdaq: GOSS) announced a structured private placement for up to approximately $250 million in gross proceeds to fund seralutinib for pulmonary arterial hypertension (PAH) and PH-ILD through potential FDA approval.
The transaction includes $150 million of committed capital: about $25 million funded at an initial closing expected on or about August 24, 2026, and about $125 million at a second closing upon FDA acceptance of the seralutinib NDA in PAH in 2026, subject to customary conditions. Investors will also receive FDA approval-triggered warrants that, if fully exercised for cash at $0.187 per share, could provide up to an additional $100 million. Securities are primarily pre-funded warrants initially exercisable into non-voting preferred stock, automatically convertible into common stock after stockholder approval. Gossamer expects the initial and committed proceeds, together with existing cash, to fund operations into 2028.
Gossamer Bio (Nasdaq: GOSS) reported second quarter 2026 net income of $16.9 million, or $0.05 basic EPS, versus a net loss of $38.3 million a year earlier, on $9.2 million in collaboration revenue and $26.4 million in R&D expenses.
The company completed a Pre-NDA Type B FDA meeting and, based on meeting minutes, plans to submit a seralutinib NDA for PAH in September 2026, targeting a potential FDA decision in the third quarter of 2027, if the application is accepted for filing.
Gossamer reacquired worldwide rights to seralutinib from Chiesi with no upfront cash payment, received a $5 million one-time payment, and will owe capped royalties and milestones. A convertible note exchange cut 5.00% 2027 Notes principal by $115.9 million. Cash, equivalents and marketable securities totaled $57.0 million, which Gossamer expects will fund operations into the first quarter of 2027.
Gossamer Bio (Nasdaq: GOSS) reported FDA, strategic, and capital structure updates centered on seralutinib for pulmonary arterial hypertension (PAH). Following a mid‑June 2026 Type B Pre‑NDA meeting and receipt of minutes, Gossamer plans a September 2026 NDA submission for PAH, supported by Phase 3 PROSERA plus Phase 2 TORREY confirmatory evidence. If filed, an FDA decision could occur in 3Q 2027.
Gossamer and Chiesi terminated their collaboration, returning worldwide development and commercial rights for seralutinib to Gossamer. Chiesi will make a $5 million one‑time payment and receive capped royalties and milestone payments, while Gossamer makes no upfront payment and regains full global operational control. At a July 14, 2026 special meeting, stockholders approved proposals tied to an exchange of $181.1 million (90.5%) of 5.00% Convertible Senior Notes due 2027 into $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030 plus equity and warrants, reducing total debt principal by about $115.9 million. Stockholders also authorized a reverse stock split to support Nasdaq bid‑price compliance, expected to be effected in or shortly after 3Q 2026, subject to Board decision. Gossamer preliminarily reported $57 million in cash, cash equivalents and marketable securities as of June 30, 2026 and announced a same‑day business update webcast.
Gossamer Bio (NASDAQ:GOSS) set key terms for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and related purchase warrants.
The initial conversion rate is 5,347.5936 shares per $1,000 principal (about $0.19 per share). The initial warrant exercise price is $0.34 per share, based on a $0.17 reference price.
Gossamer Bio (NASDAQ:GOSS) reported final results of its exchange offer for its 5.00% Convertible Senior Notes due 2027. As of June 16, 2026, no additional notes were tendered beyond the $181.052 million previously exchanged, leaving $18.948 million outstanding.
The offer provided up to $72 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317,647,058 common shares or prefunded warrants, and purchase warrants for eligible early tendering holders. A supplemental indenture removed substantially all restrictive covenants and certain events of default on the existing notes.